The purpose of this study is to determine whether estrogen may help reduce fear of high calorie-density foods in weight-restored women with Anorexia Nervosa (AN).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
AN participants will be prescribed 28 days of transdermal estradiol 0.1 mg/d (Days 1-28) plus 10 days (days 21-31) oral medroxyprogesterone 2.5 mg/d.
Johns Hopkins Hospital
Baltimore, Maryland, United States
Electrodermal skin conductance activity (EDA) during a test meal
Meal-related anxiety will be estimated from EDA recordings during a 90 minute test meal session pre- and post-treatment (day 1 and day 21). EDA will be reported as the rate of peaks (\>0.02 microsiemens) per second and the average skin conductance level (in microsiemens).
Time frame: Baseline (day 1) and post-treatment (day 21)
Heart rate variability during a test meal
Variability in heart rate will be measured by the variation in interpeak (beat-to-beat) interval during the 90 minute test meal session pre- and post- treatment (day 1 and day 21).
Time frame: Baseline (day 1) and post-treatment (day 21)
Subjective ratings of anxiety
Visual analog scales will be used to assess self-report anxiety at multiple points (time 0 min, 5 min, 10 min, 20 min, 30 min, 50 min, 70 min and 90 min) during the 90 minute test meal session pre- and post-treatment (day 1 and day 21).
Time frame: Baseline (day 1) and post-treatment (day 21)
Salivary cortisol concentration during a test meal
The concentration of salivary cortisol will be assessed at multiple points (time 0 min, 5 min, 10 min, 20 min, 30 min, 50 min, 70 min and 90 min) during the test meal session. Test meals occur twice during the entire length of the study on day 1 and day 21. The cortisol response will be reported as area under the curve.
Time frame: Baseline (day 1) and post-treatment (day 21)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.